# Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

Source: https://onco.cc/trials/nct06973343/  
OnCo record `nct06973343` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Anhui Provincial Cancer Hospital, not yet recruiting.

## Summary

Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis is a phase 2, interventional study registered as NCT06973343 by Anhui Provincial Cancer Hospital, with a registry enrolment figure of 20 participants, started 2025-05 and due to reach its primary completion in 2026-02. Interventions recorded: Group A; Group B. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: PFS. Colorectal eligibility wording from the registry: "Histologically confirmed as colorectal adenocarcinoma without liver metastasis". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06973343
- Phase: 2
- Setting: Sintilimab Plus Bevacizumab and Chemotherapy on Treatment in Patients With Advanced no Liver Metastatic MSS/pMMR Colorectal Cancer: Phase II Cohort Study
- Sponsor: Anhui Provincial Cancer Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06973343: https://clinicaltrials.gov/study/NCT06973343

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06973343.json